Recent Posts

• Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
• Sun Pharma Comes on Board as Principal Sponsor and Health Partner of Royal Challengers Bengaluru (RCB) for T20 Season 2026
• Sun Pharma reports Q3FY26 results
• Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management
• Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)